Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642222 | 0.86 | CDK1 (0.38) | TP53USP8CDK1CCNB1CCNA2 | |
| SCHEMBL12984697 | 0.79 | CDK1 (0.43) | KDM4EUSP8CDK1CCNB1CCNA2 | |
| SCHEMBL31511545 | 0.75 | PIK3CD (0.34) | TP53KDM4ECCNA2CDK2CCNA1 | |
| SCHEMBL1397037 | 0.74 | CHEK1 (0.45) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL620504 | 0.74 | USP8 (0.42) | KDM4EUSP8PIK3CD | |
| SCHEMBL5643611 | 0.69 | CDK2 (0.35) | KDM4ECDK1CCNB1CCNA2CDK2 | |
| SCHEMBL11032347 | 0.68 | PIK3CD (0.43) | KDM4EUSP8PIK3CD | |
| SCHEMBL1396879 | 0.68 | KDM4E (0.51) | KDM4E | |
| SCHEMBL15142766 | 0.68 | PIK3CD (0.40) | KDM4EUSP8PIK3CD | |
| SCHEMBL20073218 | 0.67 | ALOX5AP (0.34) | TP53PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163939-B2 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1682555-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005047294-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050096324-A1 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096324-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | TP53 686/4885KDM4E 1650/4885USP8 2745/4885 |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | TP53 686/4885KDM4E 1650/4885USP8 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.